8-K: Xencor Announces Positive Interim Phase 1 Results for XmAb942 and Plans Phase 2b Ulcerative Colitis Study

Xencor reports positive interim results from its Phase 1 study of XmAb942, an anti-TL1A antibody, and plans to initiate a Phase 2b study for ulcerative colitis in the second half of 2025.

Summary

• Xencor announced positive interim results from a Phase 1 study of XmAb942, an anti-TL1A antibody being developed for inflammatory bowel disease (IBD).
• The Phase 1 study showed that XmAb942 was well-tolerated in healthy volunteers at single and multiple doses.
• Pharmacokinetic analysis estimates a half-life of greater than 71 days, supporting a 12-week dosing interval for maintenance treatment.
• Xencor plans to initiate a Phase 2b study (XENITH-UC) of XmAb942 in patients with moderate-to-severely active ulcerative colitis (UC) in the second half of 2025.
• Lead selection for Xencor's XmAb TL1A x IL23p19 bispecific antibody program is advancing, with a first-in-human study planned for 2026.
• The company's cash position supports the advancement of its clinical portfolio.

Sentiment

Score: 8

Explanation: The document presents positive interim results from a Phase 1 study and outlines plans for further clinical development, indicating a favorable outlook for the company and its lead drug candidate.

Positives

• XmAb942 was well-tolerated in the Phase 1 study.
• The extended half-life of XmAb942 could lead to less frequent dosing, improving patient convenience.
• The Phase 2b study in ulcerative colitis is designed to efficiently support dose selection for pivotal studies.
• The XmAb TL1A x IL23p19 bispecific antibody program is advancing towards clinical trials.
• Xencor has a strong cash position to support its clinical development programs.

Risks

• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• These risks include potential delays in development timelines or negative preclinical or clinical trial results, reliance on third parties for development efforts and changes in the competitive landscape.

Future Outlook

Xencor anticipates starting a Phase 2b study in ulcerative colitis in the second half of 2025 and a Phase 1 study for its TL1A x IL23p19 bispecific antibody in 2026.

Management Comments

• Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor, stated that the Phase 1 data for XmAb942 validates the design goals for a best-in-class anti-TL1A therapy.
• He also mentioned the excitement to start the Phase 2b XENITH-UC trial and the progress in selecting a TL1A x IL23p19 bispecific lead candidate.

Industry Context

The development of XmAb942 and the TL1A x IL23p19 bispecific antibody targets the inflammatory bowel disease (IBD) market, where there is a need for novel therapies with improved efficacy, safety, and convenience compared to existing treatments.

Comparison to Industry Standards

• The document compares XmAb942 to other anti-TL1A therapies such as Tulisokibart, Afimkibart, and Duvakitug, highlighting its potential for class-leading target neutralization and convenient subcutaneous dosing.
• The document references clinical trials and data from other companies, such as Prometheus, to support the potential of XmAb942.
• The document mentions Guselkumab and Ustekinumab in Crohns Disease Based on Prior Response/Exposure to Biologic Therapy: Results from the GALAXI 2 & 3 Phase 3 Studies; Danese and Rubin et al; JNJ Presentation.
• The document mentions Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from the DISCOVER and PSUMMIT Trial; Thilakarathne and Hassan et al.; Rheumatol Ther. 2024 Feb 28.

Stakeholder Impact

• Positive results could benefit shareholders through increased stock value.
• Patients with IBD could benefit from a new treatment option with improved efficacy and convenience.
• Employees may experience increased job security and opportunities for advancement.

Next Steps

• Initiate the Phase 2b XENITH-UC study in patients with moderate-to-severely active ulcerative colitis in the second half of 2025.
• Continue lead selection for the XmAb TL1A x IL23p19 bispecific antibody program.
• Prepare for a first-in-human study of the XmAb TL1A x IL23p19 bispecific antibody planned for 2026.

Key Dates

Keywords

XmAb942, TL1A, IL23p19, ulcerative colitis, inflammatory bowel disease, Xencor, clinical trial, antibody, Xtend Fc, autoimmune, biopharmaceutical